IN2012DN03418A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03418A
IN2012DN03418A IN3418DEN2012A IN2012DN03418A IN 2012DN03418 A IN2012DN03418 A IN 2012DN03418A IN 3418DEN2012 A IN3418DEN2012 A IN 3418DEN2012A IN 2012DN03418 A IN2012DN03418 A IN 2012DN03418A
Authority
IN
India
Prior art keywords
induces
immunogenic composition
whole
response
primarily antibody
Prior art date
Application number
Other languages
English (en)
Inventor
Richard Malley
Porter Anderson
Yingjie Lu
George A Robertson
Mark Alderson
Jean-Francois Lucien Maisonneuve
Andrea Maria Tate
Oliverira Dias Waldely De
Goncalves Viviane Maimoni
Original Assignee
Childrens Medical Center
Path Vaccine Solutions
Fundacao Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Path Vaccine Solutions, Fundacao Butantan filed Critical Childrens Medical Center
Publication of IN2012DN03418A publication Critical patent/IN2012DN03418A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN3418DEN2012 2009-10-09 2010-10-12 IN2012DN03418A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25034809P 2009-10-09 2009-10-09
US38042910P 2010-09-07 2010-09-07
PCT/US2010/052298 WO2011044576A2 (en) 2009-10-09 2010-10-12 Selectively disrupted whole-cell vaccine

Publications (1)

Publication Number Publication Date
IN2012DN03418A true IN2012DN03418A (he) 2015-10-23

Family

ID=43857436

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3418DEN2012 IN2012DN03418A (he) 2009-10-09 2010-10-12

Country Status (5)

Country Link
US (1) US9827299B2 (he)
EP (1) EP2485764A4 (he)
CN (1) CN102648003B (he)
IN (1) IN2012DN03418A (he)
WO (1) WO2011044576A2 (he)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130039947A1 (en) 2010-03-12 2013-02-14 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
EP2711013A4 (en) * 2011-05-18 2015-03-04 Ajinomoto Kk IMMUNSTIMULANDS FOR ANIMALS, FEED THEREFOR AND MANUFACTURING PROCESS THEREFOR
AU2014214844B2 (en) 2013-02-07 2017-12-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
IL281204B2 (he) 2018-09-12 2025-07-01 Affinivax Inc חיסונים פנאומוקוקליים רב-ערכיים
EP4164684A4 (en) * 2020-06-12 2024-11-20 Schossau, Tom M. Inactivation of genome enveloped within coronavirus spherical or pleomorphic particles or shells to form a vaccine
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines
CN117756959B (zh) * 2024-02-22 2024-05-14 北京民海生物科技有限公司 一种肺炎链球菌荚膜多糖的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6612233A (he) * 1966-08-30 1968-03-01
NL7012832A (he) * 1970-08-29 1972-03-02
US3852420A (en) * 1971-01-20 1974-12-03 Richardson Merrell Inc Equine strangles vaccine and method of preparing and using the same
FR2174745A1 (en) * 1972-03-09 1973-10-19 Inst Elevage Med Vet Mixed veterinary vaccine - active against symptomatic and bacterial anthrax
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
US4675176A (en) 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
US5281392A (en) * 1986-03-10 1994-01-25 Rubinstein Alan I Method for disinfecting red blood cells, blood products, and corneas
DE3715840A1 (de) * 1987-05-12 1988-12-01 Boehringer Mannheim Gmbh Fuer ein lytisch wirksames, chimaeres protein kodierende rekombinante dna und ihre verwendung
GB8906795D0 (en) * 1989-03-23 1989-05-10 Carroll Noel Method of preparing vaccines
DE69019956T2 (de) * 1989-10-06 1995-11-23 Janos Szabo Pharmazeutische zusammensetzungen zur behandlung von hauterkrankungen, insbesondere pyogener und atopischer dermatitis und verfahren zu deren herstellung.
US5418130A (en) 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
ES2084057T3 (es) 1990-06-07 1996-05-01 Bayer Ag Bacterina para el tratamiento de enfermedades causadas por f. necrophorum y procedimiento para su produccion.
US6042838A (en) * 1991-02-15 2000-03-28 Uab Research Foundation immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA)
AU4114893A (en) * 1992-04-27 1993-11-29 Michigan State University Method for producing a bacterial vaccine and novel vaccines produced thereby
US6764682B1 (en) * 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
AUPN175495A0 (en) * 1995-03-14 1995-04-13 University Of New England, The Method and composition for the prevention of the over production of acid
US6743430B1 (en) * 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
DE19603649A1 (de) * 1996-02-01 1997-08-07 Werner Lubitz Rekombinante Expression von S-Layer-Proteinen
JP2001501833A (ja) * 1996-10-31 2001-02-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅのポリヌクレオチドおよび配列
IT1296148B1 (it) * 1996-11-22 1999-06-09 Renata Maria Anna Ve Cavaliere Uso di batteri lattici per accrescere il livello delle ceramidi della pelle e delle mucose, e composizioni dermatologiche e cosmetiche atte
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5958414A (en) 1997-09-03 1999-09-28 Heska Corporation Composition to protect a mammal against Bartonella henselae infection
KR20010024245A (ko) 1997-10-20 2001-03-26 조지 제이. 리코스 네오스포라 백신
US7172762B1 (en) 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
AU782508B2 (en) 1999-11-08 2005-08-04 Biomune Vaccines for mycoplasma bovis and methods of use
DE10003241A1 (de) * 2000-01-26 2001-08-02 Werner Lubitz Verschließen von Bakterienghosts
US6378677B1 (en) * 2000-10-03 2002-04-30 Honda Giken Kogyo Kabushiki Kaisha Power transmission device having electromagnetic clutch
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
AU2002314626B2 (en) * 2001-06-11 2008-01-03 Applied Nanosystems B.V. Methods for binding AcmA-type protein anchor fusions to cell-wall material of micro-organisms
EP1404808B1 (en) 2001-07-11 2010-03-31 Prof. Dr. Lubitz, Werner Nucleic acid free ghost preparations
ATE541940T1 (de) * 2001-10-15 2012-02-15 Engeneic Molecular Delivery Pty Ltd Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
EP1618884A1 (en) * 2003-04-28 2006-01-25 Sekisui Chemical Co., Ltd. Instrument for inducing cytokine and method of inducing cytokine
US7204993B2 (en) * 2004-03-18 2007-04-17 The United States Of America As Represented By The Secretary Of Agriculture Streptococcus agalactiae vaccine
US7211428B1 (en) * 2004-05-18 2007-05-01 Council Of Scientific And Industrial Research Strain of Bacillus as a bioinoculant
US7291276B1 (en) * 2004-06-21 2007-11-06 Winston Company, Inc. Controlled production and release of oxygen activated biocide into holding tanks for RV's, boats and the like
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
EP1838329B1 (en) 2004-08-17 2011-10-05 Hunter Immunology Limited Method for providing oral killed vaccines
CA2591668A1 (en) * 2004-12-14 2006-06-22 Alk-Abello A/S Pharmaceutical composition comprising a bacterial cell displaying a heterologous proteinaceous compound
EP1872794B1 (en) * 2005-04-01 2012-12-12 JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES Nasal vaccine
ES2431315T3 (es) * 2005-05-19 2013-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Epítopos funcionales del antígeno PsaA de Streptococcus pneumoniae y usos de los mismos
EP1746103A1 (en) * 2005-07-20 2007-01-24 Applied NanoSystems B.V. Bifunctional protein anchors
US8124397B2 (en) * 2005-08-08 2012-02-28 Oregon Health & Science University Inactivating pathogens with oxidizing agents for vaccine production
JP5602366B2 (ja) 2005-11-01 2014-10-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
JP2009542257A (ja) * 2006-07-10 2009-12-03 ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティ オブ アリゾナ カンピロバクター線毛タンパク質、組成物及び方法
CN101730543B (zh) * 2007-07-23 2014-02-12 疫苗研究国际有限公司 灭活的葡萄球菌全细胞疫苗
JP5722782B2 (ja) * 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
TW201043242A (en) * 2009-03-26 2010-12-16 Intervet Int Bv Vaccine for protection against Streptococcus suis bacteria of various serotypes
US8551749B2 (en) * 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
WO2010132833A1 (en) * 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
WO2011031850A1 (en) * 2009-09-10 2011-03-17 Merial Limited New vaccine formulations comprising saponin-containing adjuvants
JP2013512692A (ja) * 2009-12-07 2013-04-18 シナプティック リサーチ，リミテッド ライアビリティ カンパニー プロテアーゼ活性阻害剤の同定とプロテアーゼ活性の存在を測定するための方法

Also Published As

Publication number Publication date
EP2485764A4 (en) 2014-01-29
CN102648003A (zh) 2012-08-22
WO2011044576A2 (en) 2011-04-14
WO2011044576A3 (en) 2011-08-18
CN102648003B (zh) 2016-01-13
EP2485764A2 (en) 2012-08-15
US20120251577A1 (en) 2012-10-04
US9827299B2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
IL273607A (he) נוגדנים מאונשיים נגד liv–1, תכשירים המכילים אותם ושימושים בהם
IN2012DN03418A (he)
PH12013500810B1 (en) Anti-il-23 antibodies
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
AU2016204319A1 (en) Methods and compositions for producing squalene using yeast
MX2013011353A (es) Conjugados de anticuerpos-farmaco.
WO2010145792A8 (en) Bispecific antigen binding proteins
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
EP3038644A4 (en) Site-specific antibody conjugation methods and compositions
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
MY170720A (en) Antibody formulations
WO2009135181A3 (en) Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2012032181A3 (en) Antibody derivatives
PH12012501157A1 (en) Anti-her3 antibodies and uses thereof
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
UA101487C2 (en) Humanized b-ly1 antibody formulation
IL219801A (he) נוגדנים אנטי a4. 4c מבודדים, וקטורים המקודדים להם, שיטות להכנתם, תכשירים המכילים אותם והשימוש בהם
MX2011011512A (es) Proteinas de union de factor h quimericas (fhbp) y metodos de uso.
MX2013012184A (es) Composiciones formadoras de gel in situ.
MX2014005372A (es) Molecula portadora que comprende un antigeno spr0096 y un spr2021.